A detailed history of Bank Of America Corp transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 52,694 shares of KALV stock, worth $534,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,694
Previous 62,507 15.7%
Holding current value
$534,844
Previous $736,000 17.12%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.46 - $15.39 $92,830 - $151,022
-9,813 Reduced 15.7%
52,694 $610,000
Q2 2024

Aug 14, 2024

BUY
$10.35 - $12.49 $399,013 - $481,514
38,552 Added 160.94%
62,507 $736,000
Q1 2024

May 15, 2024

SELL
$11.07 - $16.04 $95,600 - $138,521
-8,636 Reduced 26.5%
23,955 $284,000
Q4 2023

Feb 14, 2024

BUY
$7.58 - $12.25 $87,503 - $141,414
11,544 Added 54.85%
32,591 $399,000
Q2 2023

Aug 14, 2023

SELL
$7.73 - $10.57 $13,813 - $18,888
-1,787 Reduced 7.83%
21,047 $189,000
Q1 2023

May 12, 2023

BUY
$6.3 - $8.39 $31,411 - $41,832
4,986 Added 27.94%
22,834 $179,000
Q4 2022

Feb 10, 2023

BUY
$4.2 - $14.24 $50,744 - $172,047
12,082 Added 209.54%
17,848 $120,000
Q3 2022

Nov 14, 2022

SELL
$9.85 - $16.83 $20,399 - $34,854
-2,071 Reduced 26.43%
5,766 $84,000
Q2 2022

Aug 12, 2022

SELL
$8.16 - $15.1 $507,804 - $939,688
-62,231 Reduced 88.82%
7,837 $77,000
Q1 2022

May 16, 2022

BUY
$11.2 - $16.97 $30,430 - $46,107
2,717 Added 4.03%
70,068 $1.03 Million
Q4 2021

Feb 08, 2022

BUY
$12.36 - $18.28 $668,713 - $989,002
54,103 Added 408.39%
67,351 $891,000
Q3 2021

Nov 15, 2021

BUY
$17.11 - $24.49 $26,708 - $38,228
1,561 Added 13.36%
13,248 $232,000
Q2 2021

Sep 13, 2021

BUY
$23.12 - $29.91 $270,203 - $349,558
11,687 New
11,687 $279,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $250M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.